Personalized Treatments Show Promise For Potassium Gene Epilepsies

What was studied

This paper was a systematic review about precision medicine for epilepsy linked to changes in potassium channel genes. Precision medicine means trying to match treatment to the specific gene change. The review looked at research in cell models, animal models, and humans.

The authors searched PubMed, Embase, and Cochrane for studies published up to 2025. They reviewed about 2,257 papers and included 60 studies. Most of the included studies were about KCNT1 (38 studies) and KCNQ2 (10 studies). Smaller numbers looked at KCNQ5, KCNB1, KCNA2, KCNA1, KCNA3, KCNT2, and KCNC1.

What they found

The review found that some gene-specific treatments may be promising, but the evidence is limited and variable. For KCNT1-related epilepsy, therapies that appeared effective for some patients included quinidine, cannabidiol, fluoxetine, and carvedilol. In cell and/or animal studies, bepridil and antisense oligonucleotide therapy were also supported as potential treatments. For KCNT2, there is currently no precision therapy, though cell model evidence supported quinidine, fluoxetine, loxapine, and riluzole as potential options.

For KCNQ2-related epilepsy, potential treatments included ezogabine, gabapentin, retigabine, donepezil, amitriptyline, linopirdine, pynegabine, SF0034, and XEN1101. Retigabine and gabapentin were noted as potential therapies for KCNQ5. Cannabidiol was identified as a potential therapy for KCNB1. For KCNA1 and KCNA2, 4-aminopyridine was described as useful. Gapmer antisense oligonucleotides were a potential treatment for KCNA2. Fluoxetine was listed as a potential therapy for KCNA3, and fluoxetine plus a compound called RE01 were potential therapies for KCNC1.

Limits of the evidence

This review does not show that these treatments work reliably for all patients with these gene variants. The included studies were heterogeneous, and the review states that the overall level of evidence was low. Some evidence came from cell or animal models rather than human studies.

Because the data were heterogeneous, it is hard to compare treatments directly or know which option is best. Some genes also had only 1 or 2 included studies, which further limits confidence in the findings.

For families and caregivers

For families, this review suggests that genetic testing may sometimes help identify treatment possibilities in epilepsy caused by potassium channel gene variants. It also shows growing interest in moving beyond a one-size-fits-all approach and finding therapies that better match the underlying genetic cause.

At the same time, many of these treatment ideas are not established, and some are supported only by cell or animal studies. Families may want to ask whether a child or adult's exact gene variant has any published treatment evidence and whether any suggested option has been studied in people with that specific condition.

What to watch next

Stronger evidence would come from larger, well-designed studies in people with the same gene variant, using clear measures of seizure control, side effects, and development.

Terms in this summary

precision medicine

Treatment chosen to match a person's specific disease cause, such as a gene variant.

systematic review

A study that collects and summarizes results from many earlier studies using a planned search method.

potassium channel

A protein that helps control electrical signals in nerve cells by moving potassium in and out of the cell.

gene variant

A change in a gene's DNA sequence.

antisense oligonucleotide

A lab-made genetic medicine designed to change how a gene's message is used in the body.

cell model

Research done in cells in the lab to study disease or test treatments.

animal model

Research done in animals to study disease or test treatments before human studies.

heterogeneity

Important differences across studies, such as different patients, methods, or outcomes, that make results harder to compare.